You just read:

With Novartis' Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono's Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure

News provided by

Spherix Global Insights

Jun 26, 2019, 08:00 ET